2012 Vaccine revenue: $4.11 billion

Pfizer ($PFE) continues to stand tall on the enormous success of its pneumococcal conjugate vaccine Prevnar 13, the world's best-selling vaccine. The product is approved in 120 countries and continues to nab expansions. In 2012 sales of the product hit $3.72 billion, up from $3.66 billion in 2011. Analysts anticipate revenue to hit a whopping $6.75 billion by 2018. If so, it would remain the best-selling vaccine and outsell the next-best-selling vaccine, Sanofi's ($SNY) PENTAct-HIB, by more than 3 to 1.

With such a leg to stand on, Pfizer has some wiggle room when it comes to developing new products. In December the company sold a vaccine to protect against meningitis, sepsis and pneumonia to startup Nuron Biotech for an undisclosed amount. And the company is now racing against GlaxoSmithKline ($GSK) and NovaDigm Therapeutics to come up with a vaccine to stop methicillin-resistant Staphylococcus aureus (MRSA), which kills more people in the United States than skin cancer. Two other companies failed to make an effective vaccine of this kind--most recently Merck ($MRK) in 2011. Pfizer has two candidates in early trials.

For more:
FDA expands use of Pfizer's Prevnar 13
Pfizer's Prevenar 13 gets shot in arm with WHO approval
Nuron acquires Pfizer's meningitis vaccine

-- Alison Bryant


Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.